Research & Development
EMA to decide on Pfizer's COVID-19 booster shot in early October
23 September 2021 - The European Medicines Agency (EMA), the EU's drug regulator, is expected to decide in early October on the possible use of a booster dose of the Pfizer (NYSE:PFE)/BioNTech (N...
Pfizer Inc and BioNTech announces FDA's first authorization of COVID-19 vaccine booster
23 September 2021 - Healthcare company Pfizer Inc (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) reported on Wednesday the receipt of the US Food and Drug Administration's (FDA) emergency use for the b...
US FDA authorises booster dose of Pfizer's COVID-19 booster for older and at-risk Americans
23 September 2021 - The US Food and Drug Administration (FDA) has authorised a booster dose of the Pfizer Inc (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine for those aged 65 and older, all people...
US FDA Approves Jakafi for Treatment of Chronic Graft-Versus-Host Disease
22 September 2021 - - The US Food and Drug Administration has approved Jakafi (ruxolitinib) for treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therap...
Pfizer, BioNTech Expand Collaboration with US to Provide 500 m Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries
22 September 2021 - - US-based pharmaceutical company Pfizer Inc. (NYSE: PFE) and German biotechnology company BioNTech SE (NASDAQ: BNTX) plan to expand their agreement with the US government by provi...
Poxel Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients
22 September 2021 - - French biopharmaceutical company Poxel SA (Euronext POXEL - FR0012432516) has completed enrollment in DESTINY-1 (Deuterium-stabilized R-pioglitazone (PXL065) Efficacy and Sa...
Related Headlines

Poxel Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients

Eli Lilly and Company signs supply agreement of up to 220,000 doses of bamlanivimab and etesevimab for the treatment of COVID-19 patients in Europe

Eli Lilly signs Joint Procurement Agreement with European Commission to provide bamlanivimab and etesevimab to treat COVID-19

AbbVie requests US FDA approval for risankizumab-rzaa

Abbott receives US FDA approval for Portico with FlexNav transcatheter aortic valve replacement system

Partner Therapeutics collaborates with the Biomedical Advanced Research and Development Authority

Pfizer Inc and BioNTech provides first results of pivotal trial of COVID-19 vaccine in children aged five to 11 years

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS ≥ 5

US Merck Receives Positive EU CHMP Opinion for Keytruda in Combination with Chemotherapy for Certain Patients with Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)

RhoVac completes patient recruitment for prostate cancer trial

Vicore Pharma doses first patient in global phase three C21 trial to treat COVID-19

BioFluidica to commercialise LiquidScan Automated Liquid Biopsy System

US President's chief adviser expects key data on J&J and Moderna COVID-19 boosters shots in a few weeks

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY Booster for Emergency Use in People 65 and Older and Certain High-risk Populations

European Medicines Committee Issues Positive Opinion for Qinlock for the Treatment of Fourth-line Gastrointestinal Stromal Tumor